The author and authorships in clinical trial: based on the interpretation and analysis of GPP3 / 中华医学科研管理杂志
Chinese Journal of Medical Science Research Management
; (4): 330-333, 2017.
Article
en Zh
| WPRIM
| ID: wpr-666477
Biblioteca responsable:
WPRO
ABSTRACT
Objective Clinical trial researches are sponsored by medical companies mostly,the research paper publishes in a potential publication bias inevitably.This paper discussed the author's and authorship's issues in clinical trials.Methods The Good Publication Practice for pharmaceutical companies (GPP) 3rd edition was interpreted,related literatures and domestic policies were analyzed.Results The issues including setting up publication steering committees,clarifying authorship,employing professional medical writers,personal fees,contributorship and acknowledgments,potential conflict of interest,and author's rights and obligations should be well panned and deal with in clinical trials.Conclusions Researchers who involved in clinical trials should treat the author's and authorship ’s issues with caution.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Medical Science Research Management
Año:
2017
Tipo del documento:
Article